http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 19 Oct 2026 16:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Silence+Therapeutics+++++++++++++++++/27203965.html si-local-file:///var/storage/secattach/20261019/27203965.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Silence+Therapeutics+++++++++++++++++/27203965.html Mon, 19 Oct 2026 16:10:00 -0400 SLNCF http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Silence+Therapeutics+++++++++++++++++/27201076.html si-local-file:///var/storage/secattach/20261019/27201076.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Silence+Therapeutics+++++++++++++++++/27201076.html Mon, 19 Oct 2026 08:14:00 -0400 SLNCF http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Silence+Therapeutics++++++For%3A+Oct+18/27201043.html si-local-file:///var/storage/secattach/20261019/27201043.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Silence+Therapeutics++++++For%3A+Oct+18/27201043.html Mon, 19 Oct 2026 08:06:00 -0400 SLNCF http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/Mergers+and+Acquisitions/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html <p>Merck KGaA, Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc (Nasdaq: SLN), a London-based clinical-stage biotechnology company, in a deal valuing the firm at an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion, according to a press release.</p> <p>The purchase price of $20 per American Depositary Share (ADS) in cash represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026. Each ADS represents three ordinary shares, equating to $6.6667 per ordinary share.</p> <p>The transaction will add Divesiran, a Phase 3-ready investigational siRNA therapy http://www.streetinsider.com/FDA/Merck+KGaA+to+acquire+Silence+Therapeutics+for+%241.1B/27200950.html Mon, 19 Oct 2026 08:00:43 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Press+Releases/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html <ul class="bwlistdisc"> <li> <b>Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion</b> </li> <li> <b>Silence Therapeutics is a UK-headquartered biotechnology company with a potentially best-in-class Phase 3-ready investigational siRNA therapy for rare disease, polycythemia vera (PV)</b> </li> <li> <b>Planned acquisition will strengthen the position of Merck KGaA, Darmstadt, Germany in rare diseases, a high-value growth driver, and advance its Healthcare ambition to become a leading Global Specialty Innovator</b> </li> </ul><p> <b>Not intended for UK-based media</b> </p> <p> DARMSTADT, Germany--(BUSINESS WIRE)-- Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive http://www.streetinsider.com/Business+Wire/Merck+KGaA%2C+Darmstadt%2C+Germany+to+Acquire+Silence+Therapeutics%2C+Strengthening+Rare+Disease+Pipeline+with+Innovative+siRNA+Asset/27200885.html Mon, 19 Oct 2026 08:00:00 -0400 MKKGY SLN SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/27182241.html si-local-file:///var/storage/secattach/20261013/27182241.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/27182241.html Tue, 13 Oct 2026 19:16:00 -0400 SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/27181130.html si-local-file:///var/storage/secattach/20261013/27181130.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Tetragon+Financial+Management+LP/27181130.html Tue, 13 Oct 2026 16:06:00 -0400 SLNCF http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Southland+Holdings%2C+Inc.++For%3A+Sep+30/27156054.html si-local-file:///var/storage/secattach/20261006/27156054.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Southland+Holdings%2C+Inc.++For%3A+Sep+30/27156054.html Tue, 06 Oct 2026 16:38:00 -0400 SLN SLNCF http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Southland+Holdings%2C+Inc.++For%3A+Sep+30/27156054.html si-local-file:///var/storage/secattach/20261006/27156054.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Southland+Holdings%2C+Inc.++For%3A+Sep+30/27156054.html Tue, 06 Oct 2026 16:38:00 -0400 SLN SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Griffiths+Richard+Ian/26923260.html si-local-file:///var/storage/secattach/20260813/26923260.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Griffiths+Richard+Ian/26923260.html Thu, 13 Aug 2026 21:55:00 -0400 O.00446772 SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Griffiths+Richard+Ian/26923260.html si-local-file:///var/storage/secattach/20260813/26923260.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Griffiths+Richard+Ian/26923260.html Thu, 13 Aug 2026 21:55:00 -0400 O.00446772 SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918523.html si-local-file:///var/storage/secattach/20260813/26918523.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918523.html Thu, 13 Aug 2026 11:13:00 -0400 O.00446772 SLNCF http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918523.html si-local-file:///var/storage/secattach/20260813/26918523.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Silence+Therapeutics+++++++++++++++++++Filed+by%3A+Invus+Global+Management%2C+LLC/26918523.html Thu, 13 Aug 2026 11:13:00 -0400 O.00446772 SLNCF http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Silence+Therapeutics++++++For%3A+Aug+10++Filed+by%3A+Griffiths+Richard+Ian/26918028.html si-local-file:///var/storage/secattach/20260813/26918028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Silence+Therapeutics++++++For%3A+Aug+10++Filed+by%3A+Griffiths+Richard+Ian/26918028.html Thu, 13 Aug 2026 10:07:00 -0400 O.00446772 SLNCF http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Silence+Therapeutics++++++For%3A+Aug+10++Filed+by%3A+Griffiths+Richard+Ian/26918028.html si-local-file:///var/storage/secattach/20260813/26918028.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Silence+Therapeutics++++++For%3A+Aug+10++Filed+by%3A+Griffiths+Richard+Ian/26918028.html Thu, 13 Aug 2026 10:07:00 -0400 O.00446772 SLNCF